AMPA receptor-positive allosteric modulators for the treatment of schizophrenia: An overview of recent patent applications

Future Medicinal Chemistry

Volumn 7, Issue 4, 2015, Pages 473-491

  Ward, Simon E ^a   Pennicott, Lewis E ^a   Beswick, Paul ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; NEUROLEPTIC AGENT;

ALLOSTERISM; CLINICAL RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS;

ANTIPSYCHOTIC AGENTS; HUMANS; MODELS, MOLECULAR; PATENTS AS TOPIC; RECEPTORS, AMPA; SCHIZOPHRENIA;

EID: 84928105897     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.4     Document Type: Review

References (112)

1. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl.) 179(1), 4-26 (2005).
2. Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology 56(1), 2-5 (2009).
3. Chen PE, Wyllie DJ. Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors. Br. J. Pharmacol. 147, 839-853 (2006).
4. Boulter J, Hollmann M, O'shea-Greenfield A et al. Molecular cloning and functional expression of glutamate receptor subunit genes. Science 249(4972), 1033-1037 (1990).
5. Keinanen K, Wisden W, Sommer B et al. A family of AMPA-selective glutamate receptors. Science 249(4968), 556-560 (1990).
6. Beneyto M, Meador-Woodruff JH. Expression of transcripts encoding AMPA receptor subunits and associated postsynaptic proteins in the macaque brain. J. Comp. Neurol. 468(4), 530-554 (2004).
7. Shanks NF, Maruo T, Farina AN, Ellisman MH, Nakagawa T. Contribution of the global subunit structure and stargazin on the maturation of AMPA receptors. J. Neurosci. 30(7), 2728-2740 (2010).
8. Mayer ML. Structure and mechanism of glutamate receptor ion channel assembly, activation and modulation. Curr. Opin. Neurobiol. 21(2), 283-290 (2011).
9. Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 462(7274), 745-756 (2009).
10. Mayer ML. Emerging models of glutamate receptor ion channel structure and function. Structure 19(10), 1370-1380 (2011).
11. Ward SE, Harries M, Aldegheri L et al. Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators. J. Med. Chem. 54(1), 78-94 (2011).
12. Pohlsgaard J, Frydenvang K, Madsen U, Kastrup JS. Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators. Neuropharmacology 60(1), 135-150 (2011).
13. Weeks AM, Harms JE, Partin KM, Benveniste M. Functional insight into development of positive allosteric modulators of AMPA receptors, Neuropharmacology 85, 57-66 (2014).
14. Gouaux E. Structure and function of AMPA receptors. J. Physiol. 554, 249-253 (2004).
15. Sun Y, Olson R, Horning M, Armstrong N, Mayer M, Gouaux E. Mechanism of glutamate receptor desensitization. Nature 417, 245-253 (2002).
16. Tigaret C, Choquet D. Neuroscience. More AMPAR garnish. Science 323(5919), 1295-1296 (2009).
17. Schwenk J, Harmel N, Zolles G et al. Functional proteomics identify cornichon proteins as auxiliary subunits of AMPA receptors. Science 323(5919), 1313-1319 (2009).
18. Zarate Jr. CA, Manji HK. The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. Exp. Neurol. 211(1), 7-10 (2008).
19. Albert JS, Wood MW. Targets and Emerging Therapies for Schizophrenia. Wiley-Blackwell, Oxford (2012).
20. Rankovic Z, Bingham M, Nestler EJ, Hargreaves R. Drug Discovery For Psychiatric Disorders. RSC Publishing, Cambridge (2012).
21. Cammarota M, Bevilaqua LR, Bonini JS, Rossatto JI, Medina JH, Izquierdo N. Hippocampal glutamate receptors in fear memory consolidation. Neurotox. Res. 6(3), 205-212 (2004).
22. Akhondzadeh S. The glutamate hypothesis of schizophrenia. J. Clin. Pharm. Ther. 23(4), 243-246 (1998).
23. Vignisse J, Steinbusch HW, Grigoriev V et al. Concomitant manipulation of murine NMDA- and AMPA-receptors to produce pro-cognitive drug effects in mice, Eur. Neuropsychopharmacol. 24(2), 309-20 (2014).
24. Ward SE, Harries M. Recent advances in the discovery of selective AMPA receptor positive allosteric modulators. Curr. Med. Chem. 17(30), 3503-3513 (2010).
25. Ward SE, Bax BD, Harries M. Challenges for and current status of research into positive modulators of AMPA receptors. Br. J. Pharmacol. 160(2), 181-190 (2010).
26. Arai A, Kessler M, Ambros-Ingerson J et al. Effects of a centrally active benzoylpyrrolidine drug on AMPA receptor kinetics. Neuroscience 75(2), 573-585 (1996).
27. Lynch G. Memory enhancement: the search for mechanism-based drugs. Nat. Neurosci. 5(Suppl.), 1035-1038 (2002).
28. Woolley ML, Waters KA, Gartlon JE et al. Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl.) 202(1-3), 343-354 (2009).
29. Watterson LR, Olive, MF. Are AMPA receptor positive allosteric modulators potential pharmacotherapeutics for addiction? Pharmaceuticals 7(1), 29-45, (2014).
30. Lauterborn JC, Pineda E, Chen LY, Ramirez EA, Lynch G, Gall CM. Ampakines cause sustained increases in BDNF signaling at excitatory synapses without changes in AMPA receptor subunit expression. Neuroscience 159(1), 283-295 (2009).
31. Adler LA, Kroon RA, Stein M et al. A Translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator Org 26576 in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry 72(11), 971-977 (2012).
32. Slverman JL, Oliver CF, Karras MN, Gastrell PT, Crawley JN. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology 64, 268-282 (2013).
33. Fan W, Wu X, Pan Y et al. 1-(1,3-Benzodioxol-5-yl-carbonyl) piperidine, a modulator of α - amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor, ameliorates exercise-induced fatigue in mice Biol. Pharm. Bull. 37(1), 13-17 (2014).
34. Ingvar M, Ambros-Ingerson J, Davis M et al. Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 146(2), 553-559 (1997).
35. Lynch G, Granger R, Ambros-Ingerson J, Davis CM, Kessler M, Schehr R. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp. Neurol. 145(1), 89-92 (1997).
36. Goff DC, Leahy L, Berman I et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J. Clin. Psychopharmacol. 21(5), 484-487 (2001).
37. Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 68(13), 1008-1012 (2007).
38. Berry-Kravis E, Krause SE, Block SS et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J. Child Adolesc. Psychopharmacol. 16(5), 525-40 (2006).
39. Tolerability and Primary Efficacy of CX516 in Alzheimer's Disease. https://clinicaltrials.gov/ct2/show/NCT00001662
40. A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448. https://clinicaltrials.gov/ct2/show/NCT00780585
41. Org 24448 to Treat Major Depression. https://clinicaltrials.gov/ct2/show/NCT00113022
42. Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia. https://clinicaltrials.gov/ct2/show/NCT00425815
43. Wesensten NJ, Reichardt RM, Balkin TJ. Ampakine (CX717) effects on performance and alertness during simulated night shift work. Aviat. Space Environ. Med. 78(10), 937-943 (2007).
44. Swanson GT. Targeting AMPA and kainate receptors in neurological disease: therapies on the horizon? Neuropsychopharmacology 34, 249-250 (2009).
45. Oertel BG, Felden L, Tran PV et al. Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia. Clin. Pharmacol. Ther. 87(2), 204-211 (2010).
46. Cortex's AMPAKINE CX1739 Improves Respiratory Parameters in Obstructive Sleep Apnea Patients. www.thefreelibrary.com/Cortex%27s+AMPAKINE+CX1739+Improves+Respiratory+Parameters+in... -a0248177812
47. Details of the development status of CX1739. www.cortexpharm.com
48. Nations KR, Dogterom P, Bursi R et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J. Psychopharmacol. 26(12), 1525-1539 (2012).
49. Adler LA, Kroon RA, Stein M, Shahid M, Tarazi FI. A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry 72(11), 971-977 (2012)49.
50. Chapell AS. AMPA potentiator treatment of cognitive deficits in Alzheimer disease, Neurology 68(13), 1008 (2007)
51. Trzepacz PT, Cummings J, Konechnik T et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int. Psychogeriatr. 25(5), 707-719 (2013).
52. Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers, https://clinicaltrials.gov/ct2/show/NCT00448890
53. Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD). https://clinicaltrials.gov/ct2/show/NCT02332798
54. Ward SE, Harries M, Aldegheri L et al. Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. J. Med. Chem. 53(15), 5801-5812 (2010).
55. nd ACS Natl Meet. Abst. MEDI 27 (2011).
56. Pirotte B, Francotte P, Goffin E, De Tullio P. AMPA receptor positive allosteric modulators: a patent review. Exp. Op. Ther. Patents 23(5), 615-628 (2013).
57. Bradley DM, Chan WN, Thewlis KM, Ward SE. Compounds which potentiate AMPA receptor and uses thereof in medicine: WO 2008053031A1 (2008).
58. Bertheleme N, Bradley DM, Cardullo F et al. Compounds which potentiate AMPA receptor and uses thereof in medicine: WO 2008113795A1 (2008).
59. Bradley DM, Chan WN, Harrison SA, Thewlis KM, Ward SE. Compounds which potentiate AMPA receptor and uses thereof in medicine: WO 2008110566A1 (2008).
60. Bradley DM, Thewlis KM, Ward SE. Compounds which potentiate AMPA receptor and uses thereof in medicine: WO 2008148832A1 (2008).
61. Bradley DM, Chan WN, Ward SE. Compounds which potentiate AMPA receptor and uses thereof in medicine: WO 2008148836A1 (2008).
62. Chan WN, Harrison S, Hughes OR, Neesom JK, Thewlis KM, Ward SE. Compounds which potentiate AMPA receptor and uses thereof in medicine: WO 2009053448A1 (2009).
63. Chan WN, Thewlis KM, Ward SE. Thiazoles which potentiate ampa receptor and medicinal uses thereof: WO 2009053449A1 (2009).
64. Bertheleme N, Chan WN, Scott JS, Ward SE. Compounds which potentiate the AMPA receptor and uses thereof in medicine: WO 2009080637A1 (2009).
65. Thewlis KM, Ward SE. Compounds which potentiate the AMPA receptor and uses thereof in medicine: WO 2009092712A1 (2009).
66. Thewlis KM, Ward SE. Compounds which potentiate the AMPA receptor and uses thereof in medicine: WO 2009092713A1 (2009).
67. Ward SE, Bertheleme N. Compounds which potentiate AMPA receptor and uses thereof in medicine: WO 2010037760A1 (2010).
68. Bradley DM, Cardullo F, Marshall H, Marzorati P, Pozzan A, Ward SE. Compounds which potentiate the AMPA receptor and uses thereof in medicine: WO 2010066658A1 (2010).
69. Mochizuki M, Miura S. Heterocyclic compound: WO 2009119088A1 (2009).
70. Mochizuki M, Imaeda T. Heterocyclic compound: WO 2010140339A1 (2010).
71. Mochizuki M, Imaeda T, Aso K. Heterocyclic compound: WO 2011036885A1 (2011).
72. Aso K, Mochizuki M, Miura S, Imaeda T, Toyofuku M. Heterocyclic compound: WO 2011036889A1 (2011).
73. Kori M, Imaeda T, Nakamura S et al. Heterocyclic compound and use thereof: WO 2012020848A1 (2012).
74. Fukumoto S, Ujikawa O, Morimoto S et al. Sulfonamide derivative and use thereof: WO 2012137982A2 (2012).
75. Shaffer C L, Hurst R S, Scialis R J et al. Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574. J. Pharmacol. Exp. Ther. 347, 212-224 (2013).
76. Patel N C, Schwarz J, Hou X J et al. Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators. J. Med. Chem. 56, 9180-9191 (2013).
77. Jamieson C, Basten S, Campbell R A et al. A novel series of positive modulators of the AMPA receptor: discovery and structure based hit-to-lead studies Bioorg. Med. Chem. Lett. (20), 5753-5756 (2010).
78. Jamieson C, Basten S, Campbell R A et al. A novel series of positive modulators of the AMPA receptor: structure-based lead optimization Bioorg. Med. Chem. Lett. (20) 6072-6075 (2010).
79. Timm D E, Benveniste M, Weeks AM et al. Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation. Mol. Pharmacol. 80, 267-280 (2011).
80. Mueller R, Zhong S, Hampson A et al. Benzoxazinones as potent positive allosteric AMPA receptor modulators: Part I Bioorg. Med. Chem. Lett. (21), 3923-3926 (2011).
81. Mueller R, Zhong S, Hampson A et al. Benzoxazinones as potent positive allosteric AMPA receptor modulators: Part 2 Bioorg. Med. Chem. Lett. (21), 3927-3930 (2011).
82. Mueller R, Rachwal S, Lee S et al. Benzotriazinone and benzopyrimidinone derivatives as potent positive allosteric AMPA receptor modulators Bioorg. Med. Chem. Lett. (21), 6170-6175 (2011).
83. Mueller R, Rachwal S, Varney M A et al. Benzobistriazinones and related heterocyclic ring systems as potent, orally bioavailable positive allosteric AMPA receptor modulators Bioorg. Med. Chem. Lett. (21), 7455-7459 (2011).
84. Bernard K, Danober L, Thomas JY et al. DRUG FOCUS: S 18986: a positive allosteric modulator of AMPA-type glutamate receptors pharmacological profile of a novel cognitive enhancer. CNS Neurosci. Ther. 16(5):e193-21 (2010).
85. Norholm A-B, Francotte P, Olsen L et al. Synthesis, pharmacological and structural characterization, and thermodynamic aspects of GluA2-positive allosteric modulators with a 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide scaffold. J. Med. Chem. 56, 8736-8745 (2013).
86. Dintilhac G, Arslan D, Dilly S et al. New substituted aryl esters and aryl amides of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors. Med. Chem. Commun., 2, 509-523 (2011).
87. Battisti U M, Ozwiak K, Cannazza G et al. 5-Arylbenzothiadiazine type compounds as positive allosteric modulators of AMPA/kainate receptors. ACS Med. Chem. Lett. 3(1), 25-29 (2012).
88. Cannazza G, Jozwiak K, Parenti C et al. A novel class of allosteric modulators of AMPA/Kainate receptors. Bioorg. Med, Chem. Lett. 19, 1254-1257 (2009).
89. Chen H, Wang C Z, Ding C et al. A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents. Chem. Med. Chem. 8, 226-230 (2013).
90. Estep KG, Fliri AFJJG, O'donnell C, Patel NC, Schwarz JB, Xie L. Oxopiperidinyl and pyranyl sulfonamides as AMPA potentiators: WO 2010038167A1 (2010).
91. Estep KG, O'donnell CJ, Xie L. Tetrahydrofuranyl sulfonamides for use as AMPA modulators in the treatment of CNS disorders: WO 2010041162A1 (2010).
92. Fliri AFJJ, Gallaschun RJ, O'donnell CJ, Schwarz JB, Segelstein BE. Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof: WO 2010150192A1 (2010).
93. Estep KG, Fliri AFJ, O'donnell CJ. Sulfonamides and pharmaceutical compositions thereof: WO 2008120093A1 (2008).
94. Gillen KJ, Jamieson C, Maclean JKF, Moir EM, Rankovic Z. Pyrazolealkanamide substituted thiophenes as ampa potentiators: WO 2008003452A1 (2008).
95. Gillespie J, Jamieson C, Maclean JKF, Moir EM, Rankovic Z. Indane derivatives as ampa receptor modulators: WO 2009147167A1 (2009).
96. Gallagher MG, Jamieson C, Lyons AJ, Maclean JKF, Moir EM. Heterocyclic derivatives: WO 2009062930A1 (2009).
97. Gillen KJ, Gillespie J, Jamieson C, Maclean JKF, Moir EM, Rankovic Z. Indane derivatives: WO 2010115952A1 (2010).
98. Mueller R, Lee S, O'hare S, Rogers G, Rachwal S, Street L. Benzotriazinone derivatives as AMPA receptor enhancers and their preparation, pharmaceutical compositions and use in the treatment of diseases: WO2008085505A1 (2008).
99. Cordi A, Rogers G. 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses: WO 2008085506A1 (2008).
100. Mueller R, Street LJ, Rachwal S, Alisala K. Preparation of substituted triazinone derivatives and analogs as glutamatergic synaptic response enhancers: WO2009038752A2 (2009).
101. Cordi A, Desos P, Lestage P, Danober L. Benzothiadiazepine derivatives used as AMPA and NMDA receptor modulators: WO 2010106249A1 (2010).
102. Francotte P, De Tullio P, Pirotte B, Danober L, Lestage P, Caignard D-H. New cycloalkylated benzothiadiazine derivatives, method for preparing them and pharmaceutical compositions containing them: WO 2010004139A1 (2010).
103. De Tullio P, Pirotte B, Botez L, Danober L, Lestage P. Novel derivatives of cyclopropylated benzothiadiazines, method for preparing same and pharmaceutical compositions containing same: WO 2011083265A1 (2011).
104. Francotte P, De Tullio P, Pirotte B, Botez I, Danober L, Lestage P. Thiochroman derivatives, method for preparing same and pharmaceutical compositions containing same: WO 2011083264A1.
105. Cordi A, Desos P, Lestage P, Laurence D. Dihydrobenzoxathiazepine derivatives, preparation thereof, pharmaceutical compositions and use as ampa receptor modulators: WO 2012035216A1 (2012).
106. Battisti U, Cannazza G, Puja G et al. 1,2,4-Benzothiadiazine dioxide derivatives as allosteric modulators of AMPA receptor and their preparation and use for treatment of mnemocognitive disorders: EP2457906A1 (2012).
107. Zhou, J, Chen Haijun, Johnson, K, Wang C. Bivalent AMPA receptor positive allosteric modulators: WO 2013130501A1 (2013).
108. Gouaux JE, Song L, Xie Y, Landry D. Glur2 Receptor Modulators: WO 2010087982A1 (2010).
109. Zapolsky ME, Zefirov NS, Palyulin VA et al. 4,4′-Biphenylamide derivatives having a pharmacological activity, and medicaments based thereon: WO 2012138254A2 (2012).
110. Zapolsky ME, Zefirov NS, Palyulin VA, Lavrov MI. Pharmacologically active alicyclic N,N′-substituted 3,7-diazabicyclo[3. 3. 1]nonane derivatives and drugs based thereon: WO 2012148308A1 (2012).
111. Grove S J A, Jamieson C, Maclean J F K, Morrow J A, Rankovic Z. Positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. J. Med. Chem. 53(20) 7271-7279 (2010).
112. Menniti F S, Lindsley C W, Conn P J et al. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr. Top. Med. Chem. 13(1), 26-54 (2014).